ECM
SIOX

Endurant Capital Management’s Sio Gene Therapies Inc. Common Stock SIOX Stock Holding History

Endurant Capital Management’s Portfolio SIOX Stock Details SIOX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-181,664
Closed -$1.93M – 85
2019
Q1 		$1.93M Buy
+181,664
New +$1.81M 0.76% 38

Other funds holding SIOX

SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Endurant Capital Management's SIOX Position: Q2 2019 in Review

Endurant Capital Management sold out of Sio Gene Therapies Inc. Common Stock (SIOX) in Q2 2019, closing a stake of 181,664 shares — an estimated $1.93M sold.

Endurant Capital Management first reported a position in SIOX in Q1 2019 and held it in 1 quarter. The position peaked at $1.93M in Q1 2019. 39 funds tracked by Wall St. Rank hold SIOX as of Q2 2019.

  • Endurant Capital Management reported no remaining Sio Gene Therapies Inc. Common Stock position as of Q2 2019 after selling out during the quarter.
  • Endurant Capital Management sold 181,664 Sio Gene Therapies Inc. Common Stock shares in Q2 2019, an estimated $1.93M.
  • Endurant Capital Management first reported a position in Sio Gene Therapies Inc. Common Stock in Q1 2019 and held it in 1 quarter.
  • Endurant Capital Management's Sio Gene Therapies Inc. Common Stock position peaked at $1.93M in Q1 2019.
  • 39 funds tracked by Wall St. Rank held Sio Gene Therapies Inc. Common Stock as of Q2 2019.

Based on Endurant Capital Management's 13F filing for Q2 2019, filed 14 Aug 2019.